FDA Panel OKs First Gene Therapy For Leukemia – WebMD
USA TODAY |
FDA Panel OKs First Gene Therapy For Leukemia
WebMD WEDNESDAY, July 12, 2017 (HealthDay News) — A U.S. Food and Drug Administration advisory panel on Wednesday gave unanimous approval to what could soon be the first gene therapy to be marketed in the United States. The treatment, called CTL019, … ‘Major advance’: Leukemia treatment could be first US gene therapyUSA TODAY Gene therapy to kill cancer moves a step closer to marketCNET Pioneering cancer gene therapy by Novartis backed by US panelCNBC ABC News –CBS News –Reuters –FDA all 124 news articles » |
Lupus News Today |
Phase 2 Trial of Neovacs’ Lupus Interferon Immunotherapy Receives Another Review Board Sign-off
Lupus News Today Neovacs’ Phase 2b clinical trial of an interferon immunotherapy for lupus is going according to plan, the company announced after an independent review board declined to recommend modifications to the study. The trial is evaluating interferon (IFN … |
WREX-TV |
FDA panel OKs what may soon be first gene therapy approved in US
WREX-TV (HealthDay News) — A U.S. Food and Drug Administration advisory panel on Wednesday gave unanimous approval to what could soon be the first gene therapy to be marketed in the United States. The treatment, called CTL019, genetically tweaks a patient’s … |
WREX-TV |
FDA panel OKs what may soon be first gene therapy approved in US
WREX-TV (HealthDay News) — A U.S. Food and Drug Administration advisory panel on Wednesday gave unanimous approval to what could soon be the first gene therapy to be marketed in the United States. The treatment, called CTL019, genetically tweaks a patient’s … |
|
Novel Gene Therapy for Leukemia Clears FDA Panel
Scientific American A panel of outside experts convened by the FDA voted 10-0 Wednesday to recommend the approval of Novartis’ CAR-T therapy, called CTL019, for the treatment of children and young adults with advanced leukemia. The vote marks a pivotal milestone for this … |
PMLiVE |
Novartis’ CAR–T clears FDA panel with relative ease
PMLiVE In CAR-T therapy patients’ cells are harvested and modified so they are more likely to seek out and destroy cancer cells expressing a particular antigen, in this case CD19. Once reprogrammed the T cells are infused back into the patient in order to … |